Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials [version 3; referees: 3 approved, 1 approved with reservations]
Background. Absent adaptive, individualized dose-finding in early-phase oncology trials, subsequent ‘confirmatory’ Phase III trials risk suboptimal dosing, with resulting loss of statistical power and reduced probability of technical success for the investigational therapy. While progress has been m...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2017-07-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/6-112/v3 |